Title: Proton pump inhibitor therapy after transcatheter angiography in refractory nonvariceal
acute upper gastrointestinal bleeding patients#a cohort study
Version: 0 Date: 18 Dec 2023
Reviewer's report:
A n article entitled " Proton pump inhibitor therapy after transcatheter angiography in refractory
nonvariceal acute upper gastrointestinal bleeding patients#a cohort study" by  Xue Xiao et al.
showed a role of PPI therapy for the patients with upper GI bleeding.
This article was well written, but I have some comments/ questions as the following.
1) Why the authors collected 30-day all cause mortality for primary endpoint?  I think it is better
for rebleeding rate as primary endpoint .
2) The authors divided the patents into High dose PPI group and standard PPI dose group.
The authors should clarify the reason for dividing them into two groups. Did it depend on the
prescribing physician's preference? Randomly divided?
3) I would suggest that the authors add the reason for the recurrent bleeding. Recurrent bleeding
occurred in the same lesion after embolism? or occurred other lesion of GI tract?
Title: Proton pump inhibitor therapy after transcatheter angiography in refractory nonvariceal
acute upper gastrointestinal bleeding patients#a cohort study
Version: 0 Date: 18 Dec 2023
Reviewer's report:
A n article entitled " Proton pump inhibitor therapy after transcatheter angiography in refractory
nonvariceal acute upper gastrointestinal bleeding patients#a cohort study" by  Xue Xiao et al.
showed a role of PPI therapy for the patients with upper GI bleeding.
This article was well written, but I have some comments/ questions as the following.
1) Why the authors collected 30-day all cause mortality for primary endpoint?  I think it is better
for rebleeding rate as primary endpoint .
2) The authors divided the patents into High dose PPI group and standard PPI dose group.
The authors should clarify the reason for dividing them into two groups. Did it depend on the
prescribing physician's preference? Randomly divided?
3) I would suggest that the authors add the reason for the recurrent bleeding. Recurrent bleeding
occurred in the same lesion after embolism? or occurred other lesion of GI tract?
Please review this paper.
user
Title: Proton pump inhibitor therapy after transcatheter angiography in refractory nonvariceal
acute upper gastrointestinal bleeding patients#a cohort study
Version: 0 Date: 18 Dec 2023
Reviewer's report:
A n article entitled " Proton pump inhibitor therapy after transcatheter angiography in refractory
nonvariceal acute upper gastrointestinal bleeding patients#a cohort study" by  Xue Xiao et al.
showed a role of PPI therapy for the patients with upper GI bleeding.
This article was well written, but I have some comments/ questions as the following.
1) Why the authors collected 30-day all cause mortality for primary endpoint?  I think it is better
for rebleeding rate as primary endpoint .
2) The authors divided the patents into High dose PPI group and standard PPI dose group.
The authors should clarify the reason for dividing them into two groups. Did it depend on the
prescribing physician's preference? Randomly divided?
3) I would suggest that the authors add the reason for the recurrent bleeding. Recurrent bleeding
occurred in the same lesion after embolism? or occurred other lesion of GI tract?
assistant